Mealey's (April 2, 2019, 1:35 PM EDT) -- WASHINGTON, D.C. — A New Jersey federal judge did not err in confirming that two patents directed to the treatment of polyneuropathic pain are valid but not infringed by the label of two proposed generic drugs, the Federal Circuit U.S. Court of Appeals ruled March 28 (Grünenthal GmbH, et al. v. Alkem Laboratories Limited, et al., Nos. 2017-1153, -2048, -2049, -2050, Fed. Cir., 2019 U.S. App. LEXIS 9187)....